AKT1 and colorectal carcinoma: Thirdly, butyrate reduces motility of CRC cells by inhibiting the Akt/ERK signaling pathway (Li et al., 2017), revealing the potential of butyrate as part of the therapeutic strategy for blocking metastatic CRC.